Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD)

Christine Podrini, Michela Borghesan, Azzura Greco, Valerio Pazienza, Gianluigi Mazzoccoli, Manlio Vinciguerra

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD), an accumulation of intra-hepatic triglycerides that is often considered the hepatic manifestation of insulin resistance, is the most common cause of chronic liver disease in the Western countries with up to one third of the population affected. NAFLD is a spectrum of disturbances that encompasses various degrees of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is characterized by hepatocellular injury/inflammation with or without fibrosis. The individuals with NAFLD develop NASH in 10% of the cases, and are also at risk of developing hepatocellular carcinoma (HCC). Epigenetic mechanisms of nuclear chromatin remodeling, such as DNA methylation, post-translational modifications of histones, and incorporation of histone variants into the chromatin are increasingly recognized as crucial factors in the pathophysiology of NAFLD. NAFLD is often accompanied by oxidative stress: reactive oxygen species (ROS) are implicated in altered reduction/oxidation (redox) reactions that attack cellular macromolecules and are detected in the liver of patients and animal models of NAFLD. In this review, we summarize recent knowledge advancements in the hepatic epigenetic and redox mechanisms, and their possible links, involved in the pathogenesis and treatment of NAFLD.

Original languageEnglish
Pages (from-to)2737-2746
Number of pages10
JournalCurrent Pharmaceutical Design
Volume19
Issue number15
DOIs
Publication statusPublished - 2013

Fingerprint

Epigenomics
Oxidation-Reduction
Homeostasis
Fatty Liver
Liver
Histones
Chromatin Assembly and Disassembly
DNA Methylation
Post Translational Protein Processing
Non-alcoholic Fatty Liver Disease
Chromatin
Insulin Resistance
Liver Diseases
Hepatocellular Carcinoma
Reactive Oxygen Species
Triglycerides
Oxidative Stress
Fibrosis
Chronic Disease
Animal Models

Keywords

  • Epigenetics
  • Non-alcoholic fatty liver disease (NAFLD)
  • Oxidative stress

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). / Podrini, Christine; Borghesan, Michela; Greco, Azzura; Pazienza, Valerio; Mazzoccoli, Gianluigi; Vinciguerra, Manlio.

In: Current Pharmaceutical Design, Vol. 19, No. 15, 2013, p. 2737-2746.

Research output: Contribution to journalArticle

Podrini, Christine ; Borghesan, Michela ; Greco, Azzura ; Pazienza, Valerio ; Mazzoccoli, Gianluigi ; Vinciguerra, Manlio. / Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). In: Current Pharmaceutical Design. 2013 ; Vol. 19, No. 15. pp. 2737-2746.
@article{d4c6cb36e0294b1abc9a917d9bfbd208,
title = "Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD)",
abstract = "Non-alcoholic fatty liver disease (NAFLD), an accumulation of intra-hepatic triglycerides that is often considered the hepatic manifestation of insulin resistance, is the most common cause of chronic liver disease in the Western countries with up to one third of the population affected. NAFLD is a spectrum of disturbances that encompasses various degrees of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is characterized by hepatocellular injury/inflammation with or without fibrosis. The individuals with NAFLD develop NASH in 10{\%} of the cases, and are also at risk of developing hepatocellular carcinoma (HCC). Epigenetic mechanisms of nuclear chromatin remodeling, such as DNA methylation, post-translational modifications of histones, and incorporation of histone variants into the chromatin are increasingly recognized as crucial factors in the pathophysiology of NAFLD. NAFLD is often accompanied by oxidative stress: reactive oxygen species (ROS) are implicated in altered reduction/oxidation (redox) reactions that attack cellular macromolecules and are detected in the liver of patients and animal models of NAFLD. In this review, we summarize recent knowledge advancements in the hepatic epigenetic and redox mechanisms, and their possible links, involved in the pathogenesis and treatment of NAFLD.",
keywords = "Epigenetics, Non-alcoholic fatty liver disease (NAFLD), Oxidative stress",
author = "Christine Podrini and Michela Borghesan and Azzura Greco and Valerio Pazienza and Gianluigi Mazzoccoli and Manlio Vinciguerra",
year = "2013",
doi = "10.2174/1381612811319150009",
language = "English",
volume = "19",
pages = "2737--2746",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "15",

}

TY - JOUR

T1 - Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD)

AU - Podrini, Christine

AU - Borghesan, Michela

AU - Greco, Azzura

AU - Pazienza, Valerio

AU - Mazzoccoli, Gianluigi

AU - Vinciguerra, Manlio

PY - 2013

Y1 - 2013

N2 - Non-alcoholic fatty liver disease (NAFLD), an accumulation of intra-hepatic triglycerides that is often considered the hepatic manifestation of insulin resistance, is the most common cause of chronic liver disease in the Western countries with up to one third of the population affected. NAFLD is a spectrum of disturbances that encompasses various degrees of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is characterized by hepatocellular injury/inflammation with or without fibrosis. The individuals with NAFLD develop NASH in 10% of the cases, and are also at risk of developing hepatocellular carcinoma (HCC). Epigenetic mechanisms of nuclear chromatin remodeling, such as DNA methylation, post-translational modifications of histones, and incorporation of histone variants into the chromatin are increasingly recognized as crucial factors in the pathophysiology of NAFLD. NAFLD is often accompanied by oxidative stress: reactive oxygen species (ROS) are implicated in altered reduction/oxidation (redox) reactions that attack cellular macromolecules and are detected in the liver of patients and animal models of NAFLD. In this review, we summarize recent knowledge advancements in the hepatic epigenetic and redox mechanisms, and their possible links, involved in the pathogenesis and treatment of NAFLD.

AB - Non-alcoholic fatty liver disease (NAFLD), an accumulation of intra-hepatic triglycerides that is often considered the hepatic manifestation of insulin resistance, is the most common cause of chronic liver disease in the Western countries with up to one third of the population affected. NAFLD is a spectrum of disturbances that encompasses various degrees of liver damage ranging from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH is characterized by hepatocellular injury/inflammation with or without fibrosis. The individuals with NAFLD develop NASH in 10% of the cases, and are also at risk of developing hepatocellular carcinoma (HCC). Epigenetic mechanisms of nuclear chromatin remodeling, such as DNA methylation, post-translational modifications of histones, and incorporation of histone variants into the chromatin are increasingly recognized as crucial factors in the pathophysiology of NAFLD. NAFLD is often accompanied by oxidative stress: reactive oxygen species (ROS) are implicated in altered reduction/oxidation (redox) reactions that attack cellular macromolecules and are detected in the liver of patients and animal models of NAFLD. In this review, we summarize recent knowledge advancements in the hepatic epigenetic and redox mechanisms, and their possible links, involved in the pathogenesis and treatment of NAFLD.

KW - Epigenetics

KW - Non-alcoholic fatty liver disease (NAFLD)

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84876727580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876727580&partnerID=8YFLogxK

U2 - 10.2174/1381612811319150009

DO - 10.2174/1381612811319150009

M3 - Article

C2 - 23092327

AN - SCOPUS:84876727580

VL - 19

SP - 2737

EP - 2746

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 15

ER -